



POSTER PRESENTATION

Open Access

# Pre-clinical development of BCG.HIVA(CAT) strain, an antibiotic-free selection strain for HIV-TB pediatric vaccine

N Saubi<sup>1\*</sup>, E Gea-Mallorqui<sup>1</sup>, A Mbeve-Mvula<sup>2</sup>, C Hurtado<sup>1</sup>, J Gatell<sup>1</sup>, T Hanke<sup>2</sup>, J Joseph<sup>1</sup>

From AIDS Vaccine 2012

Boston, MA, USA. 9-12 September 2012

## Background

Our starting platform was based on a heterologous BCG prime and MVA boost regimen delivering a common immunogen called HIVA. In this study, we have i) developed a BCG.HIVA<sup>CAT</sup> strain containing an antibiotic free selection system (Cobra); ii) evaluated the specific HIV-1 immune responses induced after newborn BALB/c mice immunization with BCG.HIVA<sup>CAT</sup> prime and MVA.HIVA.85A boost; iii) evaluated the specific-TB immune responses induced after newborn BALB/c mice immunization with BCG.HIVA<sup>CAT</sup> prime and MVA.HIVA.85A boost and iv) evaluated the influence of age on specific HIV-1 immune responses using the same vaccination schedule.

## Methods

7-days-old newborn and 7-weeks-old adult mice were either left unvaccinated or vaccinated subcutaneously with  $10^5$  cfu of BCG.HIVA<sup>CAT</sup> or BCGwt, and 16 weeks later were boosted intramuscularly with  $10^6$  pfu MVA.HIVA.85A. The mice were sacrificed 2 weeks later. The HIV-1 and TB-specific cellular immune responses were analyzed in spleen cells by intracellular cytokine staining and IFN- $\gamma$  ELISPOT.

## Results

The frequencies of TB-specific CD8<sup>+</sup> T-cells producing IFN- $\gamma$  (P11 stimulation), and spleen cells producing IFN- $\gamma$  (P11, P15 and PPD stimulation), were higher in BCG.HIVA<sup>CAT</sup> or BCGwt primed and MVA.HIVA.85A boosted mice compared with mice vaccinated with MVA.HIVA.85A alone (i.e. 231, 108 and 24 sfu/ $10^6$  PPD

stimulated splenocytes respectively). The specific HIV-1 immune responses (P18I10 stimulation) were lower in BCG.HIVA<sup>CAT</sup> or BCGwt primed and MVA.HIVA.85A boosted mice compared with mice vaccinated with MVA.HIVA.85A alone (i.e. 270, 276 and 412 sfu/ $10^6$  P18I10 stimulated splenocytes respectively). When adult and newborn mice were immunized using the same vaccination schedule, the HIV-1-specific immune responses in adult mice were higher than in newborn mice (0.45% vs 0.2% CD8<sup>+</sup> T-cells producing IFN  $\gamma$ ).

## Conclusion

In conclusion we demonstrated the immunogenicity of BCG.HIVA<sup>CAT</sup> and MVA.HIVA.85A in newborn mice but additional experiments should be performed in newborn mice testing different routes and doses that might provide different levels of immunogenicity.

## Author details

<sup>1</sup>AIDS Research Unit, Hospital Clinic/IDIBAPS-HIVACAT, Barcelona, Spain. <sup>2</sup>The Jenner Institute, University of Oxford, Oxford, UK.

Published: 13 September 2012

doi:10.1186/1742-4690-9-S2-P352

Cite this article as: Saubi et al.: Pre-clinical development of BCG.HIVA (CAT) strain, an antibiotic-free selection strain for HIV-TB pediatric vaccine. *Retrovirology* 2012 **9**(Suppl 2):P352.

<sup>1</sup>AIDS Research Unit, Hospital Clinic/IDIBAPS-HIVACAT, Barcelona, Spain  
Full list of author information is available at the end of the article